A recent study showed that regardless of surgical or adjuvant therapy, the median overall survival time of patients with AFP-positive HCC was much lower than those of patients with AFP-negative HCC (13 months vs. 48 months) [4]. The gene discussed is AFP; the disease is hepatocellular carcinoma.